Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved both Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for the treatment of the cardiomyopathy of wild─type or hereditary
Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved both Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for the treatment of the cardiomyopathy of wild─type or hereditary
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
